Ros1-positive Non-small Cell Lung Cancer

• FDA approval · 2023-10-20
  FDA Approved: ROZLYTREK — Original Application (Genentech, Inc.)

  Rozlytrek (entrectinib) received FDA approval in an original application for the treatment of NTRK gene fusion-positive solid tumors and ROS…

• FDA approval · 2023-08-31
  FDA Approved: ROZLYTREK — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for Rozlytrek (entrectinib) submitted by Genentech, expanding its labeling.

• FDA approval · 2023-06-16
  FDA Approved: ROZLYTREK — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for Rozlytrek (entrectinib) submitted by Genentech, Inc.

• FDA approval · 2013-09-13
  FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  The FDA approved a supplemental application for XALKORI (crizotinib) submitted by Pfizer Laboratories Div Pfizer Inc.

• FDA approval · 2013-02-28
  FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved a supplemental application for XALKORI (crizotinib) from Pfizer Laboratories Div Pfizer Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.